<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01196936</url>
  </required_header>
  <id_info>
    <org_study_id>08218</org_study_id>
    <secondary_id>R01CA140245-01</secondary_id>
    <secondary_id>NCI-2010-01976</secondary_id>
    <nct_id>NCT01196936</nct_id>
  </id_info>
  <brief_title>Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors</brief_title>
  <acronym>LDTam</acronym>
  <official_title>Low-Dose Tamoxifen for Radiation-Induced Breast Cancer Risk Reduction: A Phase IIB Randomized Placebo-Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Jude Children's Research Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>City of Hope National Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wake Forest University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen citrate
      may fight breast cancer by blocking the use of estrogen by the tumor cells

      This phase IIb trial studies how well low-dose tamoxifen citrate works in reducing breast
      cancer risk in radiation-induced cancer survivors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine the impact of a two-year course of low-dose tamoxifen (tamoxifen citrate)
      administered at 5 mg per day on surrogate endpoint biomarkers of breast cancer (BC) risk,
      including: mammographic breast density (MBD), an established radiographic biomarker of BC
      risk; cytomorphology and proliferative index, tissue biomarkers closely linked to BC risk;
      and sex steroid hormones and insulin growth factors, circulating biomarkers of BC risk.

      II. To establish safety and tolerability of this low-dose tamoxifen regimen, assessing both
      objective measures (lipid profiles, clotting factors and bone metabolism markers) and
      patient-reported outcomes.

      III. To examine the modifying effect of demographic, clinical, and molecular characteristics
      on the risk: benefit ratio from this two-year low dose tamoxifen intervention.

      IV. To explore the relationship between this low-dose tamoxifen regimen and clinical measures
      of efficacy (new breast cancer and ductal carcinoma in situ [DCIS] diagnoses) and toxicity
      (thromboembolic events, reports of hot flashes and gynecological symptoms, liver function
      abnormalities, and other cancer diagnoses).

      OUTLINE: Patients are randomized to 1 of 2 treatment arms.

      ARM I: Patients receive tamoxifen citrate orally (PO) once daily for 24 months in the absence
      of disease progression or unacceptable toxicity.

      ARM II: Patients receive placebo PO once daily for 24 months in the absence of disease
      progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up periodically for up to 10
      years.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Anticipated">December 11, 2023</completion_date>
  <primary_completion_date type="Actual">December 11, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mammographic Breast Density</measure>
    <time_frame>At year two post treatment</time_frame>
    <description>Mammographic density was quantified as percentage of fibroglandular tissue. Using an intention-to-treat analysis, mammographic breast density (MBD) was compared between patients in the low dose tamoxifen intervention and placebo group by applying the linear mixed effects model for normally distributed data.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulin Growth Factor Levels (IGF1)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>IGF1 will be treated as a continuous measure. The linear mixed effects model for between group comparisons of measures from 3 time points will be applied. The unstructured mean model and linear in time model will be employed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Grade 2-4 Toxicities</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Will be tabulated by treatment arm. Differences by treatment arm will be evaluated using Fisher exact tests.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker Levels</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Total cholesterol, low and high density lipoprotein, triglycerides, and anti-thrombin III enzymatic assay measurements will be treated as continuous variables. Transformed to normality as appropriate, the linear mixed effects model will be applied, using the unstructured mean model and linear in time model to assess the effects of low-dose tamoxifen on these measurements over time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Pills Taken Out of the Total Prescribed</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The number of pills taken out of the total prescribed in a 3-month period will be modeled as a random effects binomial regression model. The binomial rates from 8 time points (month 3-24) will be modeled as unstructured mean model with 7 indicator variables as well as polynomial models over time. The random-intercept and the random intercept and slope models will be considered. The significance of the time indicators or parameters by treatment interaction will be evaluated for treatment difference in compliance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Different Patient Reported Symptoms, Measured by Questionnaire</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The outcomes will be scored as a 5-point Likert-type scale (0-4) in response to questions on how much the patients are bothered by certain symptoms. The questionnaire will be administered every 6 months. The responses will be treated as normally distributed, as ordinal or dichotomized variable, and the linear mixed effects of general linear mixed model (GLMM) methods will be applied to compare changes between treatment groups. Piecewise models will also be fitted with join point at 6 months, considering linear and curvilinear trajectories between 6 and 24 month time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin Growth Factor Levels (IGF3 )</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>IGF3 will be treated as a continuous measure. The linear mixed effects model for between group comparisons of measures from 3 time points will be applied. The unstructured mean model and linear in time model will be employed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker Levels - Alkaline Phosphatase</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Serum bone-specific alkaline phosphatase measurements will be treated as continuous variables. Transformed to normality as appropriate, the linear mixed effects model will be applied, using the unstructured mean model and linear in time model to assess the effects of low-dose tamoxifen on these measurements over time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker Levels - Urine N-telopeptide</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Urine n-telopeptide measurements will be treated as continuous variables. Transformed to normality as appropriate, the linear mixed effects model will be applied, using the unstructured mean model and linear in time model to assess the effects of low-dose tamoxifen on these measurements over time.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I (tamoxifen citrate)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive tamoxifen citrate PO QD for 24 months in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive placebo PO QD for 24 months in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamoxifen Citrate</intervention_name>
    <description>5 mg PO Daily</description>
    <arm_group_label>Arm I (tamoxifen citrate)</arm_group_label>
    <other_name>Marketed under trade name Nolvadex as 10 mg and 20 mg tablets</other_name>
    <other_name>ICI 46,474</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 tablet daily</description>
    <arm_group_label>Arm II (placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Digital mammography</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (tamoxifen citrate)</arm_group_label>
    <arm_group_label>Arm II (placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunohistochemistry staining method</intervention_name>
    <description>Correlative Studies</description>
    <arm_group_label>Arm I (tamoxifen citrate)</arm_group_label>
    <arm_group_label>Arm II (placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative Studies</description>
    <arm_group_label>Arm I (tamoxifen citrate)</arm_group_label>
    <arm_group_label>Arm II (placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative Studies</description>
    <arm_group_label>Arm I (tamoxifen citrate)</arm_group_label>
    <arm_group_label>Arm II (placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>protein expression analysis</intervention_name>
    <description>correlative studies</description>
    <arm_group_label>Arm I (tamoxifen citrate)</arm_group_label>
    <arm_group_label>Arm II (placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacogenomic studies</intervention_name>
    <description>correlative studies</description>
    <arm_group_label>Arm I (tamoxifen citrate)</arm_group_label>
    <arm_group_label>Arm II (placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>questionnaire administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (tamoxifen citrate)</arm_group_label>
    <arm_group_label>Arm II (placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Fine needle aspiration</intervention_name>
    <arm_group_label>Arm I (tamoxifen citrate)</arm_group_label>
    <arm_group_label>Arm II (placebo)</arm_group_label>
    <other_name>Correlative studies</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality of Life Assessment</intervention_name>
    <description>Ancillary Studies</description>
    <arm_group_label>Arm I (tamoxifen citrate)</arm_group_label>
    <arm_group_label>Arm II (placebo)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Exposure to radiation therapy (RT) delivered to the chest, axilla, and/or
             supraclavicular areas at a cumulative dose of 12 Gy or more by age 40 years; in
             addition, patients who received total body irradiation by age 40 may be considered

          -  No evidence of active disease from their primary cancer for at least 2 continuous
             years prior to registration; the indication for RT is not specified but cannot be for
             primary breast cancer; common examples include, but are not limited to: lymphoma,
             leukemia, sarcoma, and Wilms tumor occurring in pediatric patients, and lymphoma,
             leukemia, and sarcoma occurring in young adults; primary cancer therapy must have been
             completed at least 6 months prior to registration

          -  Well-defined menopausal status falling into one of the following categories:

               -  Premenopausal, defined as age at registration 45 years old or younger with
                  regular monthly period for at least 6 consecutive months prior to registration

               -  Postmenopausal, defined as continuous absence of menstruation for 12 months OR
                  status-post bilateral oophorectomy OR follicle stimulating hormone (FSH) level in
                  the postmenopausal range

        Exclusion Criteria:

          -  Subsequent malignant neoplasm (SMN) other than those listed below diagnosed within 2
             years of study entry; patients with the listed indolent or pre-invasive neoplasms may
             be eligible if diagnosed within 2 years and all treatment was completed at least 6
             months prior to registration:

               -  Non-melanoma cancers of the skin

               -  Thyroid cancer

               -  Cervical cancer confined to the cervix or cervical intraepithelial neoplasia
                  (CIN)

               -  Ductal carcinoma in situ (DCIS) or breast intraepithelial neoplasia (IEN)
                  (includes atypical hyperplasia and lobular carcinoma in situ [LCIS]), or

               -  Superficial or non-invasive transitional cell carcinoma of the bladder

          -  For women with a prior history of DCIS or breast IEN, only one breast could have been
             involved and all therapy must have been completed at least 6 months prior to
             registration; in addition women with a prior history of invasive breast cancer may
             also be eligible, as long as only one breast was involved, they were diagnosed at
             least 2 years prior to study entry, and therapy was completed at least 6 months prior
             to study entry

          -  Bilateral breast implants or status-post bilateral prophylactic mastectomy

          -  Evidence of malignant breast disease on any form of breast imaging; the study only
             requires annual mammography; however, annual breast magnetic resonance imaging (MRI)
             is considered standard of care in this patient population (per Children's Oncology
             Group [COG] or National Comprehensive Cancer Network [NCCN] follow-up guidelines), and
             breast ultrasound may be indicated if a palpable lesion is detected on screening
             clinical breast exam; abnormal imaging may require additional radiographs and/or
             breast biopsy; patients who are found to have benign breast disease with or without
             atypia may continue on study as long as there is no evidence of malignancy; if there
             is evidence of malignancy, and only one breast is involved, they may be reapproached 6
             months after completion of therapy for consideration of the trial

          -  Baseline categorical mammographic density scored as BIRAD 1, or extremely fatty, in
             both breasts; if the patient has a prior history of IEN (DCIS, LCIS, or atypical
             hyperplasia), the contralateral breast must not have a mammographic density score of
             BIRAD 1; this determination will be made at the local site

          -  Current or recent use (within 6 months of registration or baseline mammogram,
             whichever is first) of any of the following: systemic hormone replacement therapy
             (includes oral or transdermal formulations); Vagifem and Estring, two formulations of
             locally applied vaginal estrogen associated with minimal systemic absorption, may be
             allowed; other estrogen-containing vaginal creams, while not an exclusion, should be
             avoided whenever possible; patients with a history of hormone modifying herbal
             supplements are eligible, but patients will be asked to avoid their use after on study

          -  Current or recent use (within 6 months of registration or baseline mammogram,
             whichever is first) of any of the following: hormonal forms of contraception (includes
             oral, transdermal, implanted, and injectable formulations): selective estrogen
             receptor modifiers; aromatase inhibitors; GnRH analogs; androgens or antiandrogens

          -  Concurrent use of warfarin and strong inhibitors or CYP2D6 will not be allowed

          -  A personal history or a strong family of thromboembolism, including deep venous
             thrombosis (DVT), pulmonary embolus (PE), or cerebrovascular accident (CVA); a
             personal history of transient ischemic attack (TIA) or retinal vein thrombosis will
             also not be allowed; in addition, patients with a condition known to increase
             hypercoagulability, such as Factor V Leiden disease, will be excluded; patients with
             atrial fibrillation will be excluded, due to risk of CVA, but patients with coronary
             artery disease or congestive heart failure without atrial fibrillation will be allowed
             to participate

          -  Current intrauterine pregnancy or plans to become pregnant within two years; in
             addition, currently nursing mothers will be excluded

          -  Serum creatinine &gt; 2X the institutional norm

          -  Total bilirubin &gt; 2X the institutional norm

          -  Serum glutamic oxaloacetic transaminase (SGOT) or serum glutamic pyruvic transaminase
             (SGPT) &gt; 2X the institutional norm

          -  Unable to provide consent
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Smita Bhatia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado, Anschutz Medical Campus</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-5718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Health Network, Toronto</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>September 3, 2010</study_first_submitted>
  <study_first_submitted_qc>September 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2010</study_first_posted>
  <results_first_submitted>December 10, 2019</results_first_submitted>
  <results_first_submitted_qc>January 14, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 27, 2020</results_first_posted>
  <last_update_submitted>January 14, 2020</last_update_submitted>
  <last_update_submitted_qc>January 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Smitia Bhatia</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Cancer survivors</keyword>
  <keyword>Low Dose Tamoxifen</keyword>
  <keyword>Breast Cancer Risk Reduction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 26, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/36/NCT01196936/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were screened for eligibility at each participating institution.However, after central review of mammograms, 11 participants were ineligible for the study (mammographic density &lt;25%) and 1 participant was randomized but withdrew before taking the study drug. These 12 participants were excluded from the analysis.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm I (Tamoxifen Citrate)</title>
          <description>Patients receive tamoxifen citrate PO QD for 24 months in the absence of disease progression or unacceptable toxicity.
Tamoxifen Citrate: 5 mg PO Daily
Digital mammography: Correlative studies
immunohistochemistry staining method: Correlative Studies
pharmacological study: Correlative Studies
laboratory biomarker analysis: Correlative Studies
protein expression analysis: correlative studies
pharmacogenomic studies: correlative studies
questionnaire administration: Ancillary studies
Fine needle aspiration
Quality of Life Assessment: Ancillary Studies</description>
        </group>
        <group group_id="P2">
          <title>Arm II (Placebo)</title>
          <description>Patients receive placebo PO QD for 24 months in the absence of disease progression or unacceptable toxicity.
Placebo: 1 tablet daily
Digital mammography: Correlative studies
immunohistochemistry staining method: Correlative Studies
pharmacological study: Correlative Studies
laboratory biomarker analysis: Correlative Studies
protein expression analysis: correlative studies
pharmacogenomic studies: correlative studies
questionnaire administration: Ancillary studies
Fine needle aspiration
Quality of Life Assessment: Ancillary Studies</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Year One Post Treatment</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm I (Tamoxifen Citrate)</title>
          <description>Patients receive tamoxifen citrate PO QD for 24 months in the absence of disease progression or unacceptable toxicity.
Tamoxifen Citrate: 5 mg PO Daily
Digital mammography: Correlative studies
immunohistochemistry staining method: Correlative Studies
pharmacological study: Correlative Studies
laboratory biomarker analysis: Correlative Studies
protein expression analysis: correlative studies
pharmacogenomic studies: correlative studies
questionnaire administration: Ancillary studies
Fine needle aspiration
Quality of Life Assessment: Ancillary Studies</description>
        </group>
        <group group_id="B2">
          <title>Arm II (Placebo)</title>
          <description>Patients receive placebo PO QD for 24 months in the absence of disease progression or unacceptable toxicity.
Placebo: 1 tablet daily
Digital mammography: Correlative studies
immunohistochemistry staining method: Correlative Studies
pharmacological study: Correlative Studies
laboratory biomarker analysis: Correlative Studies
protein expression analysis: correlative studies
pharmacogenomic studies: correlative studies
questionnaire administration: Ancillary studies
Fine needle aspiration
Quality of Life Assessment: Ancillary Studies</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="34"/>
            <count group_id="B2" value="38"/>
            <count group_id="B3" value="72"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.7" lower_limit="34.3" upper_limit="48.8"/>
                    <measurement group_id="B2" value="44.1" lower_limit="34.6" upper_limit="47.0"/>
                    <measurement group_id="B3" value="43.8" lower_limit="34.5" upper_limit="48.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="72"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mammographic Breast Density</title>
        <description>Mammographic density was quantified as percentage of fibroglandular tissue. Using an intention-to-treat analysis, mammographic breast density (MBD) was compared between patients in the low dose tamoxifen intervention and placebo group by applying the linear mixed effects model for normally distributed data.</description>
        <time_frame>At year two post treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Tamoxifen Citrate)</title>
            <description>Patients receive tamoxifen citrate PO QD for 24 months in the absence of disease progression or unacceptable toxicity.
Tamoxifen Citrate: 5 mg PO Daily
Digital mammography: Correlative studies
immunohistochemistry staining method: Correlative Studies
pharmacological study: Correlative Studies
laboratory biomarker analysis: Correlative Studies
protein expression analysis: correlative studies
pharmacogenomic studies: correlative studies
questionnaire administration: Ancillary studies
Fine needle aspiration
Quality of Life Assessment: Ancillary Studies</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Placebo)</title>
            <description>Patients receive placebo PO QD for 24 months in the absence of disease progression or unacceptable toxicity.
Placebo: 1 tablet daily
Digital mammography: Correlative studies
immunohistochemistry staining method: Correlative Studies
pharmacological study: Correlative Studies
laboratory biomarker analysis: Correlative Studies
protein expression analysis: correlative studies
pharmacogenomic studies: correlative studies
questionnaire administration: Ancillary studies
Fine needle aspiration
Quality of Life Assessment: Ancillary Studies</description>
          </group>
        </group_list>
        <measure>
          <title>Mammographic Breast Density</title>
          <description>Mammographic density was quantified as percentage of fibroglandular tissue. Using an intention-to-treat analysis, mammographic breast density (MBD) was compared between patients in the low dose tamoxifen intervention and placebo group by applying the linear mixed effects model for normally distributed data.</description>
          <units>percentage of fibrogladular tissue</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.2" spread="2.4"/>
                    <measurement group_id="O2" value="48.6" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.05</p_value>
            <p_value_desc>The calculated p-value is 0.05.</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insulin Growth Factor Levels (IGF1)</title>
        <description>IGF1 will be treated as a continuous measure. The linear mixed effects model for between group comparisons of measures from 3 time points will be applied. The unstructured mean model and linear in time model will be employed.</description>
        <time_frame>Up to 2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Tamoxifen Citrate)</title>
            <description>Patients receive tamoxifen citrate PO QD for 24 months in the absence of disease progression or unacceptable toxicity.
Tamoxifen Citrate: 5 mg PO Daily
Digital mammography: Correlative studies
immunohistochemistry staining method: Correlative Studies
pharmacological study: Correlative Studies
laboratory biomarker analysis: Correlative Studies
protein expression analysis: correlative studies
pharmacogenomic studies: correlative studies
questionnaire administration: Ancillary studies
Fine needle aspiration
Quality of Life Assessment: Ancillary Studies</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Placebo)</title>
            <description>Patients receive placebo PO QD for 24 months in the absence of disease progression or unacceptable toxicity.
Placebo: 1 tablet daily
Digital mammography: Correlative studies
immunohistochemistry staining method: Correlative Studies
pharmacological study: Correlative Studies
laboratory biomarker analysis: Correlative Studies
protein expression analysis: correlative studies
pharmacogenomic studies: correlative studies
questionnaire administration: Ancillary studies
Fine needle aspiration
Quality of Life Assessment: Ancillary Studies</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Growth Factor Levels (IGF1)</title>
          <description>IGF1 will be treated as a continuous measure. The linear mixed effects model for between group comparisons of measures from 3 time points will be applied. The unstructured mean model and linear in time model will be employed.</description>
          <units>ng/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144.3" spread="7.1"/>
                    <measurement group_id="O2" value="162.3" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0266</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Grade 2-4 Toxicities</title>
        <description>Will be tabulated by treatment arm. Differences by treatment arm will be evaluated using Fisher exact tests.</description>
        <time_frame>Up to 2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Tamoxifen Citrate)</title>
            <description>Patients receive tamoxifen citrate PO QD for 24 months in the absence of disease progression or unacceptable toxicity.
Tamoxifen Citrate: 5 mg PO Daily
Digital mammography: Correlative studies
immunohistochemistry staining method: Correlative Studies
pharmacological study: Correlative Studies
laboratory biomarker analysis: Correlative Studies
protein expression analysis: correlative studies
pharmacogenomic studies: correlative studies
questionnaire administration: Ancillary studies
Fine needle aspiration
Quality of Life Assessment: Ancillary Studies</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Placebo)</title>
            <description>Patients receive placebo PO QD for 24 months in the absence of disease progression or unacceptable toxicity.
Placebo: 1 tablet daily
Digital mammography: Correlative studies
immunohistochemistry staining method: Correlative Studies
pharmacological study: Correlative Studies
laboratory biomarker analysis: Correlative Studies
protein expression analysis: correlative studies
pharmacogenomic studies: correlative studies
questionnaire administration: Ancillary studies
Fine needle aspiration
Quality of Life Assessment: Ancillary Studies</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Grade 2-4 Toxicities</title>
          <description>Will be tabulated by treatment arm. Differences by treatment arm will be evaluated using Fisher exact tests.</description>
          <units>Adverse Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.12</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biomarker Levels</title>
        <description>Total cholesterol, low and high density lipoprotein, triglycerides, and anti-thrombin III enzymatic assay measurements will be treated as continuous variables. Transformed to normality as appropriate, the linear mixed effects model will be applied, using the unstructured mean model and linear in time model to assess the effects of low-dose tamoxifen on these measurements over time.</description>
        <time_frame>Up to 2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Tamoxifen Citrate)</title>
            <description>Patients receive tamoxifen citrate PO QD for 24 months in the absence of disease progression or unacceptable toxicity.
Tamoxifen Citrate: 5 mg PO Daily
Digital mammography: Correlative studies
immunohistochemistry staining method: Correlative Studies
pharmacological study: Correlative Studies
laboratory biomarker analysis: Correlative Studies
protein expression analysis: correlative studies
pharmacogenomic studies: correlative studies
questionnaire administration: Ancillary studies
Fine needle aspiration
Quality of Life Assessment: Ancillary Studies</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Placebo)</title>
            <description>Patients receive placebo PO QD for 24 months in the absence of disease progression or unacceptable toxicity.
Placebo: 1 tablet daily
Digital mammography: Correlative studies
immunohistochemistry staining method: Correlative Studies
pharmacological study: Correlative Studies
laboratory biomarker analysis: Correlative Studies
protein expression analysis: correlative studies
pharmacogenomic studies: correlative studies
questionnaire administration: Ancillary studies
Fine needle aspiration
Quality of Life Assessment: Ancillary Studies</description>
          </group>
        </group_list>
        <measure>
          <title>Biomarker Levels</title>
          <description>Total cholesterol, low and high density lipoprotein, triglycerides, and anti-thrombin III enzymatic assay measurements will be treated as continuous variables. Transformed to normality as appropriate, the linear mixed effects model will be applied, using the unstructured mean model and linear in time model to assess the effects of low-dose tamoxifen on these measurements over time.</description>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="189.9" spread="7.1"/>
                    <measurement group_id="O2" value="192.5" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low-density lipoprotein</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105.4" spread="5.7"/>
                    <measurement group_id="O2" value="108.6" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High-density lipoprotein</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.6" spread="3.0"/>
                    <measurement group_id="O2" value="56.5" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138.1" spread="13.2"/>
                    <measurement group_id="O2" value="116.6" spread="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-thrombin III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.3" spread="5.4"/>
                    <measurement group_id="O2" value="98.1" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Pills Taken Out of the Total Prescribed</title>
        <description>The number of pills taken out of the total prescribed in a 3-month period will be modeled as a random effects binomial regression model. The binomial rates from 8 time points (month 3-24) will be modeled as unstructured mean model with 7 indicator variables as well as polynomial models over time. The random-intercept and the random intercept and slope models will be considered. The significance of the time indicators or parameters by treatment interaction will be evaluated for treatment difference in compliance.</description>
        <time_frame>Up to 2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Tamoxifen Citrate)</title>
            <description>Patients receive tamoxifen citrate PO QD for 24 months in the absence of disease progression or unacceptable toxicity.
Tamoxifen Citrate: 5 mg PO Daily
Digital mammography: Correlative studies
immunohistochemistry staining method: Correlative Studies
pharmacological study: Correlative Studies
laboratory biomarker analysis: Correlative Studies
protein expression analysis: correlative studies
pharmacogenomic studies: correlative studies
questionnaire administration: Ancillary studies
Fine needle aspiration
Quality of Life Assessment: Ancillary Studies</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Placebo)</title>
            <description>Patients receive placebo PO QD for 24 months in the absence of disease progression or unacceptable toxicity.
Placebo: 1 tablet daily
Digital mammography: Correlative studies
immunohistochemistry staining method: Correlative Studies
pharmacological study: Correlative Studies
laboratory biomarker analysis: Correlative Studies
protein expression analysis: correlative studies
pharmacogenomic studies: correlative studies
questionnaire administration: Ancillary studies
Fine needle aspiration
Quality of Life Assessment: Ancillary Studies</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Pills Taken Out of the Total Prescribed</title>
          <description>The number of pills taken out of the total prescribed in a 3-month period will be modeled as a random effects binomial regression model. The binomial rates from 8 time points (month 3-24) will be modeled as unstructured mean model with 7 indicator variables as well as polynomial models over time. The random-intercept and the random intercept and slope models will be considered. The significance of the time indicators or parameters by treatment interaction will be evaluated for treatment difference in compliance.</description>
          <units>percentage of pills taken</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.5" lower_limit="56.1" upper_limit="100"/>
                    <measurement group_id="O2" value="96.7" lower_limit="20.7" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.78</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Different Patient Reported Symptoms, Measured by Questionnaire</title>
        <description>The outcomes will be scored as a 5-point Likert-type scale (0-4) in response to questions on how much the patients are bothered by certain symptoms. The questionnaire will be administered every 6 months. The responses will be treated as normally distributed, as ordinal or dichotomized variable, and the linear mixed effects of general linear mixed model (GLMM) methods will be applied to compare changes between treatment groups. Piecewise models will also be fitted with join point at 6 months, considering linear and curvilinear trajectories between 6 and 24 month time points.</description>
        <time_frame>Up to 2 years</time_frame>
        <population>Symptoms with &gt;10% prevalence are reported; patients were dichotomized into 2 groups: those that rated the symptom as moderately or extremely bothersome vs. slightly or quite a bit bothersome</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Tamoxifen Citrate)</title>
            <description>Patients receive tamoxifen citrate PO QD for 24 months in the absence of disease progression or unacceptable toxicity.
Tamoxifen Citrate: 5 mg PO Daily
Digital mammography: Correlative studies
immunohistochemistry staining method: Correlative Studies
pharmacological study: Correlative Studies
laboratory biomarker analysis: Correlative Studies
protein expression analysis: correlative studies
pharmacogenomic studies: correlative studies
questionnaire administration: Ancillary studies
Fine needle aspiration
Quality of Life Assessment: Ancillary Studies</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Placebo)</title>
            <description>Patients receive placebo PO QD for 24 months in the absence of disease progression or unacceptable toxicity.
Placebo: 1 tablet daily
Digital mammography: Correlative studies
immunohistochemistry staining method: Correlative Studies
pharmacological study: Correlative Studies
laboratory biomarker analysis: Correlative Studies
protein expression analysis: correlative studies
pharmacogenomic studies: correlative studies
questionnaire administration: Ancillary studies
Fine needle aspiration
Quality of Life Assessment: Ancillary Studies</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Different Patient Reported Symptoms, Measured by Questionnaire</title>
          <description>The outcomes will be scored as a 5-point Likert-type scale (0-4) in response to questions on how much the patients are bothered by certain symptoms. The questionnaire will be administered every 6 months. The responses will be treated as normally distributed, as ordinal or dichotomized variable, and the linear mixed effects of general linear mixed model (GLMM) methods will be applied to compare changes between treatment groups. Piecewise models will also be fitted with join point at 6 months, considering linear and curvilinear trajectories between 6 and 24 month time points.</description>
          <population>Symptoms with &gt;10% prevalence are reported; patients were dichotomized into 2 groups: those that rated the symptom as moderately or extremely bothersome vs. slightly or quite a bit bothersome</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Interrupted sleep</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General aches or pains</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hot flashes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint pain or stiffness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Feeling unusually tired</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heartburn and/or acid stomach</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headaches</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle cramps or soreness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt; 0.05</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insulin Growth Factor Levels (IGF3 )</title>
        <description>IGF3 will be treated as a continuous measure. The linear mixed effects model for between group comparisons of measures from 3 time points will be applied. The unstructured mean model and linear in time model will be employed.</description>
        <time_frame>Up to 2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Tamoxifen Citrate)</title>
            <description>Patients receive tamoxifen citrate PO QD for 24 months in the absence of disease progression or unacceptable toxicity.
Tamoxifen Citrate: 5 mg PO Daily
Digital mammography: Correlative studies
immunohistochemistry staining method: Correlative Studies
pharmacological study: Correlative Studies
laboratory biomarker analysis: Correlative Studies
protein expression analysis: correlative studies
pharmacogenomic studies: correlative studies
questionnaire administration: Ancillary studies
Fine needle aspiration
Quality of Life Assessment: Ancillary Studies</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Placebo)</title>
            <description>Patients receive placebo PO QD for 24 months in the absence of disease progression or unacceptable toxicity.
Placebo: 1 tablet daily
Digital mammography: Correlative studies
immunohistochemistry staining method: Correlative Studies
pharmacological study: Correlative Studies
laboratory biomarker analysis: Correlative Studies
protein expression analysis: correlative studies
pharmacogenomic studies: correlative studies
questionnaire administration: Ancillary studies
Fine needle aspiration
Quality of Life Assessment: Ancillary Studies</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Growth Factor Levels (IGF3 )</title>
          <description>IGF3 will be treated as a continuous measure. The linear mixed effects model for between group comparisons of measures from 3 time points will be applied. The unstructured mean model and linear in time model will be employed.</description>
          <units>ng/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4716.0" spread="168.0"/>
                    <measurement group_id="O2" value="4315.2" spread="170.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.071</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biomarker Levels - Alkaline Phosphatase</title>
        <description>Serum bone-specific alkaline phosphatase measurements will be treated as continuous variables. Transformed to normality as appropriate, the linear mixed effects model will be applied, using the unstructured mean model and linear in time model to assess the effects of low-dose tamoxifen on these measurements over time.</description>
        <time_frame>Up to 2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Tamoxifen Citrate)</title>
            <description>Patients receive tamoxifen citrate PO QD for 24 months in the absence of disease progression or unacceptable toxicity.
Tamoxifen Citrate: 5 mg PO Daily
Digital mammography: Correlative studies
immunohistochemistry staining method: Correlative Studies
pharmacological study: Correlative Studies
laboratory biomarker analysis: Correlative Studies
protein expression analysis: correlative studies
pharmacogenomic studies: correlative studies
questionnaire administration: Ancillary studies
Fine needle aspiration
Quality of Life Assessment: Ancillary Studies</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Placebo)</title>
            <description>Patients receive placebo PO QD for 24 months in the absence of disease progression or unacceptable toxicity.
Placebo: 1 tablet daily
Digital mammography: Correlative studies
immunohistochemistry staining method: Correlative Studies
pharmacological study: Correlative Studies
laboratory biomarker analysis: Correlative Studies
protein expression analysis: correlative studies
pharmacogenomic studies: correlative studies
questionnaire administration: Ancillary studies
Fine needle aspiration
Quality of Life Assessment: Ancillary Studies</description>
          </group>
        </group_list>
        <measure>
          <title>Biomarker Levels - Alkaline Phosphatase</title>
          <description>Serum bone-specific alkaline phosphatase measurements will be treated as continuous variables. Transformed to normality as appropriate, the linear mixed effects model will be applied, using the unstructured mean model and linear in time model to assess the effects of low-dose tamoxifen on these measurements over time.</description>
          <units>ug/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.2" spread="0.7"/>
                    <measurement group_id="O2" value="12.4" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.739</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biomarker Levels - Urine N-telopeptide</title>
        <description>Urine n-telopeptide measurements will be treated as continuous variables. Transformed to normality as appropriate, the linear mixed effects model will be applied, using the unstructured mean model and linear in time model to assess the effects of low-dose tamoxifen on these measurements over time.</description>
        <time_frame>Up to 2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Tamoxifen Citrate)</title>
            <description>Patients receive tamoxifen citrate PO QD for 24 months in the absence of disease progression or unacceptable toxicity.
Tamoxifen Citrate: 5 mg PO Daily
Digital mammography: Correlative studies
immunohistochemistry staining method: Correlative Studies
pharmacological study: Correlative Studies
laboratory biomarker analysis: Correlative Studies
protein expression analysis: correlative studies
pharmacogenomic studies: correlative studies
questionnaire administration: Ancillary studies
Fine needle aspiration
Quality of Life Assessment: Ancillary Studies</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Placebo)</title>
            <description>Patients receive placebo PO QD for 24 months in the absence of disease progression or unacceptable toxicity.
Placebo: 1 tablet daily
Digital mammography: Correlative studies
immunohistochemistry staining method: Correlative Studies
pharmacological study: Correlative Studies
laboratory biomarker analysis: Correlative Studies
protein expression analysis: correlative studies
pharmacogenomic studies: correlative studies
questionnaire administration: Ancillary studies
Fine needle aspiration
Quality of Life Assessment: Ancillary Studies</description>
          </group>
        </group_list>
        <measure>
          <title>Biomarker Levels - Urine N-telopeptide</title>
          <description>Urine n-telopeptide measurements will be treated as continuous variables. Transformed to normality as appropriate, the linear mixed effects model will be applied, using the unstructured mean model and linear in time model to assess the effects of low-dose tamoxifen on these measurements over time.</description>
          <units>nM Bone Collagen Equiv. / nM Creatinine</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.1" spread="3.6"/>
                    <measurement group_id="O2" value="32.0" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8315</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected every six months while the participants were on the two year study.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Arm I (Tamoxifen Citrate)</title>
          <description>Patients receive tamoxifen citrate PO QD for 24 months in the absence of disease progression or unacceptable toxicity.
Tamoxifen Citrate: 5 mg PO Daily
Digital mammography: Correlative studies
immunohistochemistry staining method: Correlative Studies
pharmacological study: Correlative Studies
laboratory biomarker analysis: Correlative Studies
protein expression analysis: correlative studies
pharmacogenomic studies: correlative studies
questionnaire administration: Ancillary studies
Fine needle aspiration
Quality of Life Assessment: Ancillary Studies</description>
        </group>
        <group group_id="E2">
          <title>Arm II (Placebo)</title>
          <description>Patients receive placebo PO QD for 24 months in the absence of disease progression or unacceptable toxicity.
Placebo: 1 tablet daily
Digital mammography: Correlative studies
immunohistochemistry staining method: Correlative Studies
pharmacological study: Correlative Studies
laboratory biomarker analysis: Correlative Studies
protein expression analysis: correlative studies
pharmacogenomic studies: correlative studies
questionnaire administration: Ancillary studies
Fine needle aspiration
Quality of Life Assessment: Ancillary Studies</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasm malignant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endrocrine disorders - Other</sub_title>
                <description>Night sweats</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorders - other</sub_title>
                <description>Increased appetite, decreased appetite</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Gastroesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Bloating</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>General disorders - Other</sub_title>
                <description>Fluid retention, intolerance of cold, intolerance of heat</description>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Generalized muscle weakness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorder - Other</sub_title>
                <description>Leg cramps</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Nervous system disorders - Other</sub_title>
                <description>Easily distracted, clumsiness</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Concentration impairment</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric disorders - Other</sub_title>
                <description>Mood swings, Unhappy with body appearance</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary frequency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Cystitis noninfective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Renal and urinary disorders - Other</sub_title>
                <description>burning upon urination; strong urine smell</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Irregular menstruation</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Breast pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Reproductive system and breast disorders-Other</sub_title>
                <description>Vaginal dryness, vaginal spotting, genital itching/irritation</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Vaginal Hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Vaginal discharge</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Dyspareunia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Rash acneiform</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Slower than expected accrual, and financial constraints of supporting the study drug costs necessitated study closure before attainment of planned study enrollment.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Smita Bhatia</name_or_title>
      <organization>University of Alabama at Birmingham</organization>
      <phone>(205) 638-2120</phone>
      <email>sbhatia@peds.uab.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

